Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06270706 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Pliant Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 124
- Enrollment target
NCT06270706: Recruiting Phase 1 study, sponsored by Pliant Therapeutics.
NCT06270706 is a Phase 1 study that is actively recruiting participants, run by Pliant Therapeutics. The registered enrollment target is 124 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (107% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06270706, a Phase 1 study, is actively recruiting participants, sponsored by Pliant Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 124 participants
- Enrollment target
Study Summary
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory \[primary resistance\]) or relapsed \[secondary resistance\]) after at least 3 months from the start of treatment with pembrolizumab. The study will consist of 2 main parts: * Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with accelerated titration * Part 2: Dose-expansion cohorts using Simon's 2-stage design
Primary Outcome
Number of participants with a Dose Limiting Toxicity (DLT) defined as toxicities that meet predefined severity criteria, assess as having a suspected relationship to study drug, unrelated to disease, inter-current illness, or concomitant medications.
Interventions
- DRUG PLN-101095
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2023-08-30 |
| Est. Completion | 2030-06 |
| Phase | Phase 1 |
What NCT06270706 shows while recruiting
NCT06270706 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (107% higher).
The record links to 0 conditions, and to 1 intervention - of which PLN-101095 is the first listed.
NCT06270706 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06270706 about?
NCT06270706 is a clinical study titled "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors". This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or met...
What is the current status of trial NCT06270706?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2023-08-30. Estimated completion is 2030-06.
What interventions are being tested in trial NCT06270706?
The interventions under investigation include: PLN-101095 (DRUG).
Who is sponsoring clinical trial NCT06270706?
This trial is sponsored by Pliant Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06270706's enrollment target sits among peer trials
124 471st of 2000 higher than 1,526 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI